FDA Approves MEPRON — GlaxoSmithKline LLC
GlaxoSmithKline announced the FDA approval of oral Atovaquone (Mepron) for the treatment of Pneumocystis pneumonia, a strategic addition expected to broaden the company’s portfolio and capture market share in the oral antiprotozoal segment.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day